Isosceles Pharmaceuticals is developing parenteral analgesics that utilize the body's endocannabinoid system to provide rapid onset pain relief for acute pain, without relying on opioids or NSAIDs. The company addresses the unmet need for effective non-opioid pain management solutions in the perioperative setting.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Post-operative acute pain management often relies on opioid-based analgesics, which carry risks of addiction and adverse side effects. Non-opioid alternatives like NSAIDs may not provide sufficient pain relief or may be contraindicated for certain patients. There is an unmet need for effective, non-addictive pain management solutions with rapid onset for acute pain.
Solution
Isosceles Pharmaceuticals is developing a pipeline of parenteral analgesics that leverage the body's endocannabinoid system to deliver rapid-onset pain relief for acute pain, without the use of opioids or NSAIDs. Their intravenous formulations of synthetic Cannabidiol (CBD) are designed as a non-addictive alternative to opioid painkillers for post-operative pain management. In addition, they are developing an intradermal microneedle formulation for a "microneedle patch" to be used in pain management. These products aim to provide physicians with new alternatives for effective and safe pain relief.
Target Audience
The primary target audience includes physicians and hospitals seeking non-opioid, non-NSAID alternatives for acute pain management in the perioperative setting.
Features
- Intravenous formulations of synthetic Cannabidiol (CBD) for rapid onset pain relief.
- Microneedle patch formulation for intradermal delivery of analgesics.
- Targets the endocannabinoid system to reduce pain and inflammation.
- Designed as a non-addictive alternative to opioid-based pain medications.
- Aims to reduce reliance on NSAIDs and their associated side effects.